Interactive Antimicrobial Profiles of Astragalus membranaceus (Fisch.) Bunge Extracts and Conventional Antibiotics against Pathogenic and Non-pathogenic Gastrointestinal Bacteria


Pharmacognosy Communications,2018,8,4,158-164.
Published:October 2018
Type:Original Article

Interactive Antimicrobial Profiles of Astragalus membranaceus (Fisch.) Bunge Extracts and Conventional Antibiotics against Pathogenic and Non-pathogenic Gastrointestinal Bacteria

Wenjing Lai1,2, Ian Edwin Cock3,4, Matthew James Cheesman1,5*

1School of Pharmacy and Pharmacology, Gold Coast Campus, Griffith University, Parklands Drive, Southport, Queensland 4222, AUSTRALIA.

2College of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, CHINA.

3School of Environment and Science, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Queensland 4111, AUSTRALIA.

4Environmental Futures Research Institute, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Queensland 4111, AUSTRALIA.

5Menzies Health Institute Queensland, Quality Use of Medicines Network, Queensland 4222, AUSTRALIA.


Background: The aim of this project was to investigate the efficacy of Astragalus membranaceus (Astragalus) extracts, alone and in combination with conventional antibiotics, against diarrhoea- and dysentery-causing pathogens, as well as against non-pathogenic gastrointestinal bacterial strains. The study sought to validate the chemotherapeutic potential of a traditional Chinese medicinal plant and to identify combinational therapies with increased efficacy compared to either the extracts or conventional antibiotics alone. Methods: Astragalus root powder was extracted with solvents of varying polarity and screened for inhibition of bacterial growth. Susceptibility was assessed by disc diffusion techniques, whilst the minimum inhibitory concentrations (MICs) were quantified by liquid dilution assays. To screen for combinatorial effects, the Astragalus root extracts were combined with a range of conventional antibiotics and tested against each bacterial strain using liquid dilution assays. ΣFIC values were determined and used to determine the class of interaction. Results: Aqueous Astragalus root extracts did not significantly inhibit the growth of the non-pathogenic or beneficial gut microflora bacteria E. cloacae, E. coli or E. faecalis, but possessed mild inhibitory activity against pathogenic A. faecalis, A. hydrophila, B. cereus, S. newport and S. sonnei bacteria. Combinations of the Astragalus extracts and conventional antibiotics generally produced additive or indifferent interactions, indicating that they are safe to use concomitantly without compromising the efficacy of either component. Two cases of antagonistic combinations were detected against B. cereus and S. sonnei. Conclusion: Mild inhibition of 5 pathogenic bacteria occurred with aqueous Astragalus extracts, with a number of additive and antagonistic interactions arising when tested in combination with conventional antibiotics. Astragalus may be used safely in the presence of normal gut bacteria and in most combinations with conventional antibiotics.

Founded:  In 2004, as the PHCOG.NET – a non-profit private organization dedicated to Natural Products Research leading to develop promising drugs. Our main mission is to make information on herbal drug research readily available in different formats to suit the individual needs.

Pharmacognosy Communications [Phcog Commn.] is a new quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the  publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.

The journal aims to cater the latest outstanding developments in the field of pharmacognosy and natural products and drug design covering but not limited to the following topics:

  • Pharmacognosy and pharmacognistic investigations
  • Research based ethnopharmacological evaluations
  • Biological evaluation of crude extracts, essential oils and pure isolates
  • Natural product discovery and evaluation
  • Mechanistic studies
  • Method and technique development and evaluation
  • Isolation, identification and structural elucidation of natural products
  • Synthesis and transformation studies

Distinctions:  The most widely read, cited, and known Pharmacognosy Communications and website is well browsed with all the articles published. More than 20,000 readers in nearly every country in the world each month

Aim and Scope | Editorial Board | Indexed & Abstracted | Instruction to Authors | Manuscript Submission & Charges

Subjects Covered : Natural Products, Pharmacognosy, Phytochemistry, Marine Pharmacognosy and Zoo Pharmacognosy
ISSN :2249-0159 (Print) ; 2249-0167 (Online) Frequency : Quarterly Rapid at a time publication (4 issues/year)

Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online  publication is 45 days.
Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.